Codexis Partners With siRNA Innovator on Stereo-Defined Synthesis
REDWOOD CITY, Calif. — September 28, 2026 Codexis, Inc. announced an agreement with a pioneering siRNA drug innovator to...
RNAi
Advertisement
Wave Initiates Phase 2a WVE-007 Combination Trial for Obesity
CAMBRIDGE, Mass. — September 23, 2026 Wave Life Sciences announced the initiation of a Phase 2a clinical trial evaluating...
Arrowhead Advances ARO-DIMER-PA in Mixed Hyperlipidemia
PASADENA, Calif. — September 15, 2026 Arrowhead Pharmaceuticals, Inc. announced interim topline clinical data from the Phase 1/2a ARODIMER-PA-1001...
Moonwalk Biosciences Raises $70 Million Series B
SOUTH SAN FRANCISCO and SAN DIEGO — September 8, 2026 Moonwalk Biosciences announced the closing of an oversubscribed $70...
Tangram Therapeutics Advances TGM-312 Into MASH Patient Cohorts
London, UK, September 3, 2026 Tangram Therapeutics announced that its investigational MASH treatment TGM-312 has progressed into Part B...
Advertisements
Alnylam Presents ATTR-CM Data at ESC Congress 2026
Cambridge, Mass. – August 30, 2026 Alnylam Pharmaceuticals announced new clinical data at the European Society of Cardiology (ESC)...
Arrowhead Reports Phase 3 Plozasiran Data Reducing Pancreatitis
Pasadena, Calif. – August 30, 2026 Arrowhead Pharmaceuticals presented detailed Phase 3 SHASTA-3 and SHASTA-4 data showing that plozasiran...
Arrowhead Expands REDEMPLO Access for FCS in Germany
PASADENA, Calif., August 17, 2026 Arrowhead Pharmaceuticals, Inc. announced that people living with familial chylomicronaemia syndrome (FCS) in Germany...
Phio Pharmaceuticals Reports Positive PH-762 Skin Cancer Data
KING OF PRUSSIA, PENNSYLVANIA, March 23, 2026 Phio Pharmaceuticals Corp. has announced the presentation of positive clinical study results...
Tangram Advances TGM-312 With Phase 1/2 CTA Submission
LONDON — November 26, 2025. Tangram Therapeutics has submitted a Clinical Trial Application (CTA) to the UK Medicines and...
Advertisement
